The dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients were significantly larger and more differentiated than the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients. The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.